The round was led by Arsenal Capital Management.
The company intends to use the funds:
- to complete integration and expand manufacturing capacity of recently acquired Biosensia and its ISO 13485-certified facilities in Dublin, Ireland;
- to support commercial launch of additional Kypha tests; and
- to expand partnerships with pharmaceutical companies advancing several promising new therapies targeting complement, a central arm of the immune system.
Led by Chad Stiening, CEO, Kypha provides an innovative testing platform for precision monitoring of immune system activity to improve patient care and advance immune-targeted drug development. Its platform can enable complement testing at scale from home health to clinical laboratory, to support precision immune monitoring as standard of care in a growing multi-billion dollar complement drug and immunotherapy marketplace.
Biosensia, which operates as a Kypha wholly-owned subsidiary in Dublin, Ireland is a science and engineering focused company established to develop, manufacture, and commercialize multi-analyte quantitative and qualitative assays on a low-complexity, CLIA-waived testing platform. The company also offers contract assay development and manufacturing services, and its facilities are ISO 13485-certified.
FinSMEs
20/12/2018